Page results
-
The Ataxia Centre brings together a team of specialists, with expertise in the diagnosis, management and research of all forms of ataxia.
-
Information about the integrated women's service at the Royal London Hospital for Integrated Medicine
-
Information about the integrated cancer care service at the Royal London Hospital for Integrated Medicine.
-
Overview of the UCLH ambulatory care service for adults with cancer. This service allows people to have their cancer treatment at outpatient appointments, without needing to stay overnight in hospital.
-
This information outlines the things that you need to take home after your robotic prostatectomy.
-
This page provides information for patients visiting the Inflammatory Bowel Disease clinic.
-
ME/CFS is a condition where chronic fatigue is not, much relieved by rest. It affects daily functioning and may also trigger joint pains, mood and sleep disturbance, concentration difficulties, headaches, intestinal and urinary symptoms.
-
This information describes the different types of anaesthetic you might require for your operation.
-
Information about the integrated physiotherapy service at the Royal London Hospital for Integrated Medicine.
-
As part of Together Type 1, Diabetes UK are excited to invite young people to join an engaging online ‘Type 1 Chat’.
File results
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment